丹参酮ⅡA磺酸钠和布地奈德格隆溴铵福莫特罗联合治疗慢性阻塞性肺疾病急性加重期的临床研究  

Clinical study of Danshen ketone Ⅱ A sodium sulfonate combined with budesonide-formoterol and tiotropium bromide for acute exacerbation of chronic obstructive pulmonary disease

作　　者：宣瑞萍 查日田 Xuan Ruiping;Cha Ritian(Department of Respiratory Medicine,the First People's Hospital of Wuhu,Wuhui 241000,Anhui,China)

机构地区：[1]芜湖市第一人民医院呼吸内科,安徽芜湖241000

出　　处：《中国中西医结合急救杂志》2024年第1期41-45,共5页Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care

基　　金：安徽省芜湖市卫生健康委科研和技技术才项目(2019WWKJ02)。

摘　　要：目的观察在布地奈德格隆溴铵福莫特罗基础上加用丹参酮ⅡA磺酸钠对慢性阻塞性肺疾病急性加重期(AECOPD)患者的临床疗效。方法选择芜湖市第一人民医院2021年9月至2023年9月收治的112例AECOPD患者作为研究对象。按病情严重程度将患者分为对照组和研究组,每组56例。对照组给予布地奈德格隆溴铵福莫特罗雾化吸入治疗,研究组给予布地奈德格隆溴铵福莫特罗雾化吸入联合丹参酮ⅡA磺酸钠治疗。治疗10d后,比较两组肺功能、血气指标和血液学指标的差异,并观察不良反应发生情况。结果与治疗前比较,两组治疗后第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1/FVC、动脉血氧分压(PaO_(2))、超氧化物歧化酶(SOD)、谷胱甘肽(CSH)均明显升高[对照组:FEV1(L)为59.76±11.43比53.71±5.62,FVC(L)为63.54±6.19比55.28±7.51,FEV1/FVC为(59.48±8.15)%比(53.96±8.43)%,PaO_(2)(mmHg,1mmHg~0.133kPa)为76.93±4.58比68.95±4.96,S0D(kU/L)为83.19±6.58比70.41±5.57,CSH(mg/L)为242.89±21.78比218.31±46.52;研究组:FEV1(L)为65.83±10.35比52.49±5.41,FVC(L)为69.41±10.73比53.31±8.36,FEV1/FVC为(67.62±7.35)%比(52.71±7.33)%,PaO(mmHg)为83.21±5.34比70.32±5.31,S0D(kU/L)为90.32±7.14比71.63±5.94,GSH(mg/L)为264.33±26.14比213.67±41.36],动脉血二氧化碳分压(PaCO_(2))、白细胞介素(IL-1β、IL-6)、肿瘤坏死因子-α(TNF-α)均明显降低[对照组:PaCO_(2)(mmHg)为53.56±5.14比59.16±5.59,IL-1β(ng/L)为6.43±1.71比8.53±3.89,IL-6(ng/L)为18.64±2.13比25.31±4.19,TNF-α(ng/L)为81.72±10.79比102.58±14.31;研究组:PaCO_(2)(mmHg)为47.13±5.42比61.37±6.08,IL-1β(ng/L)为5.16±1.37比9.01±4.13,IL-6(ng/L)为10.52±2.43比25.84±4.27,TNF-α(ng/L)为61.35±12.81比104.35±16.51],差异均有统计学意义(均P<0.05),且以研究组的变化更明显。研究组治疗前后FEV1、FVC、FEV1/FVC、PaO_(2)、PaCO_(2)、IL-1β、IL-6、TNF-α、SOD、GSH的差值△FEV1、△FVC、△FEV1/FVC、△PaO_(2)、△PaCO_(2)�Objective To observe the clinical efficacy of Danshen ketoneⅡA sodium sulfonate combined with budesonide-formoterol and tiotropium bromide in the treatment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods A total of 112 AECOPD patients admitted to the First People's Hospital of Wuhu from September 2021 to September 2023 were selected as the research objects.According to the severity of the disease,the patients were divided into the control group and the study group,with 56 cases in each group.The control group received aerosol inhalation of budesonide-formoterol and tiotropium bromide,while the study group was treated with budesonide-formoterol and tiotropium bromide combined with Danshen ketoneⅡA sodium sulfonate.After 10 days of treatment,the lung function,blood gas indexes,hematological indexes,and adverse reactions were compared between the two groups.Results Compared to pre-treatment levels,the forced expiratory volume in one second(FEV1),forced vital capacity(FVC),FEV1/FVC,arterial partial pressure of oxygen(PaO_(2)),superoxide dismutase(SOD)and glutathione(GSH)were significantly increased in the two groups after treatment[control group:FEV1(L)was 59.76±11.43 vs.53.71±5.62,FVC(L)was 63.54±6.19 vs.55.28±7.51,FEV1/FVC was(59.48±8.15)%vs.(53.96±8.43)%,PaO_(2)(mmHg,1 mmHg~0.133 kPa)was 76.93±4.58 vs.68.95±4.96,SOD(kU/L)was 83.19±6.58 vs.70.41±5.57,GSH(mg/L)was 242.89±21.78 vs.218.31±46.52;study group:FEV1(L)was 65.83±10.35 vs.52.49±5.41,FVC(L)was 69.41±10.73 vs.53.31±8.36,FEV1/FVC was(67.62±7.35)%vs.(52.71±7.33)%,PaO_(2)(mmHg)was 83.21±5.34 vs.70.32±5.31,SOD(kU/L)was 90.32±7.14 vs.71.63±5.94,CSH(mg/L)was 264.33±26.14 vs.213.67±41.36,all P<0.05],while the arterial partial pressure of carbon dioxide(PaCO_(2)),interleukins(IL-1β,IL-6),tumor necrosis factor-Q(TNF-α)exhibited significant decreases[control group:PaCO_(2)(mmHg)was 53.56±5.14 vs.59.16±5.59,IL-1β(ng/L)was 6.43±1.71 vs.8.53±3.89,IL-6(ng/L)was 18.64±2.13 vs.25.31±4.19,TNF-α(ng/L)was 81.72

关 键 词：慢性阻塞肺疾病急性加重期 布地奈德 格隆溴铵 福莫特罗 丹参酮ⅡA磺酸钠 炎症细胞因子 

分 类 号：R259[医药卫生—中西医结合]